Samsung, covid, Oppo, Smartphone sales, coronavirus, Vivo, Covid wave, Canalys

Smartphone shipments in India fell 13 per cent to 32.4 million units in the April-June 2021 period over the previous quarter as the second wave of COVID-19 stifled demand, according to research firm Canalys. Given that the April-June 2020 had an almost two-month nationwide lockdown (amid the first wave of the pandemic), the year-on-year comparison was “extremely favorable” with shipments up 87 per cent, Canalys said in its report.

Xiaomi continued to remain the top player with 29 per cent market share (9.5 million units shipment) in the June 2021 quarter, followed by Samsung stayed in second place with 17 per cent share (5.5 million) and

Vivo

with 5.4 million.

Realme overtook Oppo for fourth place, shipping 4.9 million units (15 per cent) against Oppo‘s 3.8 million (12 per cent) in the said period, the report said.

A surge in COVID-19 cases prompted regional restrictions and economic disruption, which limited consumers’ disposable income.

“India was taken by surprise by its second wave, as the new COVID variant emerged and took hold quickly. For smartphone vendors, this was a wake-up call, and shows the importance of bolstering both online and offline presences equally,” Canalys Analyst Sanyam Chaurasia said.

Signs of a recovery did emerge by the end of the second quarter as consumer confidence was boosted by vaccination programmes in key localities.

India will rebound in the second half of 2021, aided by accelerated vaccinations, as well as brands expanding promotional activities and new product releases, Chaurasia said.

“But the second half will not see a surge in pent-up demand like last year. The threat of a third wave still looms in India, but as citizen behavior and industrial operations continue to adapt to pandemic conditions, its impact should be minimal,” he added.

Chaurasia noted that increasing costs will be challenging, amid limited component supply, rising shipping charges and a tough macroeconomic environment.

“In the short term, vendors will bear the impact of supply chain disruption, and will be conservative about raising prices. But the component shortage also brings another risk – regional deprioritization – as brands look to allocate their limited supplies of devices to more lucrative markets,” he said.


Japan travel news, japan travel guides, japan holiday destinations and japan reviews

LATEST NEWS

NEWS RELATED

Dr Reddy's waiting for 2.7 million doses of Sputnik V 2nd jab from Russia for full rollout

Representative image of the Russian Sputnik V COVID-19 vaccine Dr Reddy’s said it was waiting for 2.7 million doses of Sputnik V COVID-19 vaccine from Russia for second jab, for the full fledged rollout of the vaccine. “We have received 150000 of both the dose 1 and dose 2, following…

Read more: Dr Reddy's waiting for 2.7 million doses of Sputnik V 2nd jab from Russia for full rollout

Brazil scraps Covaxin's EUA application after Bharat Biotech terminates pact with partners

Bharat Biotech’s Covaxin was granted restricted emergency use approval in ‘clinical trial mode’ on January 2. After suspending the proposed clinical trials of Bharat Bioetchs COVID-19 vaccine Covaxin, Brazil has now scrapped the Emergency Use Authorisation request made by the Indian company for the jab. The Brazilian health regulator’s decisioncomesafter…

Read more: Brazil scraps Covaxin's EUA application after Bharat Biotech terminates pact with partners

Biocon Biologics, Adagio Therapeutics sign pact for potential antibody treatment against COVID-19

“We expect results from the phase 4 study on itolizumab by the end of this quarter. This would be real-world data from around 300 patients,” said Arun Chandavarkar, Managing Director of Biocon Biologics (Representative image) Biocon Biologics, the subsidiary of Biocon on July 26 said that US-based Adagio Therapeutics has…

Read more: Biocon Biologics, Adagio Therapeutics sign pact for potential antibody treatment against COVID-19

Jubilant Pharmova profit jumps 350% to Rs 160 crore in Q1FY22

On import alert issued by USFDA last week on the company’s Roorkee formulations manufacturing facility, the company said it was engaging with the agency and taking help of consultants to resolve the regulatory compliance issues. Jubilant Pharmova on July 13 reported net profit of Rs 160 crore in Q1FY22, a…

Read more: Jubilant Pharmova profit jumps 350% to Rs 160 crore in Q1FY22

Explained | Why UK expert panel advised against giving COVID-19 jabs to all children aged 12-17

The Joint Committee on Vaccination and Immunisation (JCVI), the UK’s top body of independent experts, has advised its government to defer vaccinating all children aged 12-17, saying only children at increased risk of serious COVID-19 disease should be offered the Pfizer-BioNTech vaccine. The JCVI, which is the equivalent of India’s…

Read more: Explained | Why UK expert panel advised against giving COVID-19 jabs to all children aged 12-17

Bharat Biotech commits to supply 500 million doses of Covaxin to Centre for immunisation programme

Covaxin, Bharat Biotech Bharat Biotech on Friday said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation programme. Speaking at a virtual conference organised by the Confederation of Indian Industry, Suchitra Ella, joint Managing Director of the city-based…

Read more: Bharat Biotech commits to supply 500 million doses of Covaxin to Centre for immunisation programme

Biocon profit drops 44% in Q1FY22 due to subdued generics business, exceptional item

Biocon Biocon, on July 23, reported a 44 percent year-on-year (YoY) drop in net profit to Rs 84 crore in the first quarter ended June due to subdued API business and an exceptional item. Profit for the same period last year was Rs 149 crore. Net Profit stood at Rs…

Read more: Biocon profit drops 44% in Q1FY22 due to subdued generics business, exceptional item

Gland Pharma on track to start production of Sputnik V jabs by November

Gland Pharma | Representative image Gland Pharma, a generic injectable focused pharmaceutical company, said it is on track to begin production of Sputnik V COVID-19 vaccines from October-November. Technology transfer of the drug substance to its manufacturing facility is under way, the company said. A dedicated manufacturing unit at Pashamylaram…

Read more: Gland Pharma on track to start production of Sputnik V jabs by November

Infosys reopens offices as India Inc eyes long road back to work

Gland Pharma Q1FY22 profit rises 12% on new launches, COVID drugs Remdesivir and Enoxaparin

Syngene posts Rs 77.3 net profit in Q1FY22, gets boost from sales of COVID drug remdesivir

Top life insurers raise provisions as COVID-19 claims pinch hard

COVID-19 impact | How technology can help fight physician burnout

Institutional investment in real estate to grow 4% to Rs 36,500 crore in 2021 despite COVID: Report

Restrictions, weekend closures continue to ail retailing business

WHO assessing Covaxin data for EUL; Decision date "to be confirmed"

OTHER NEWS